# The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

> **NCT05829057** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 10 (estimated)

## Conditions studied

- Esophagus Cancer
- Bladder Cancer
- Liver Cancer
- Ovarian Cancer
- Small-cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Intravenous injection of P-IL-2
- **BIOLOGICAL:** P-IL-2 plus Anti-PD-1 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT05829057
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-23
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-21
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05829057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05829057, "The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT05829057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*